Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Skin disease, therapy

Many patents have been issued on the use of pyrogaUol derivatives as pharmaceuticals. PyrogaUol has been used extemaUy in the form of an ointment or a solution in the treatment of skin diseases, eg, psoriasis, ringworm, and lupus erythematosus. GaUamine triethiodide (16) is an important muscle relaxant in surgery it also is used in convulsive-shock therapy. Trimethoprim (2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine) is an antimicrobial and is a component of Bactrin and Septra. Trimetazidine (l(2,3,4-trimethoxybenzyl)piperazine (Vastarel, Yosimilon) is used as a coronary vasodilator. l,2,3,4-Tetrahydro-6-methoxy-l-(3,4,5-trimethoxyphenyl)-9JT-pyrido[3,4- ]indole hydrochloride is useful as a tranquilizer (52) (see Hypnotics, sedatives, ANTICONVULSANTS, AND ANXIOLYTICS). Substituted indanones made from pyrogaUol trimethyl ether depress the central nervous system (CNS) (53). Tyrosine-and glycine(2,3,4-trihydroxybenzyl)hydrazides are characterized by antidepressant and anti-Parkinson activity (54). [Pg.378]

Since the tragic human exposure to diethyltin salts for the therapy of an infectious skin disease by Staphylococcus in France in the 1950s, the toxic and biochemical effects of many of these derivatives have been explored. Di- and tri-ethyltin salts have been demonstrated to have pronounced effects on intermediary metabolism in brain and liver. These effects have been suggested to be due to inhibition of the mitochondrial functions9,27. [Pg.891]

This work finally resulted in a new protocol for treating psoriasis, a chronic skin disease that can be seriously debilitating. The patient receives successive oral doses of methoxsalen followed by ultraviolet irradiation of the affected areas of skin. The procedure effectively controls psoriasis, and with improvements incorporated over the past twenty years it has become a standard therapy. Related procedures bring relief from several other skin diseases. In addition, the combination of psoralens and light has a key role in a promising treatment now under development for a white blood cell cancer. [Pg.164]

Particles from cationic lipids may also be useful for antisense therapy of skin disease — a nontoxic increase in the oligonucleotide uptake by cultivated keratinocytes and a sebocyte cell line has been reported [66]. Moreover, cationic dendri-mers also efficiently transfer reporter gene DNA to human keratinocytes cultivated in vitro. In the skin of hairless mice, in vivo transfection was possible with complexes, yet reporter gene expression was localized to perifollicular areas. Transfection, however, failed with the naked plasmid. For prolonged contact, biodegradable membranes coated with dendrimer/DNA complexes were used [67]. This hints at a follicular uptake of these complexes and indicates that gene transfection also may be possible with human skin, which has a thicker stratum comeum compared with mouse skin (eight to ten vs. two to three layers [58]). [Pg.12]

Hydroxychloroquine is approved for the treatment of both systemic and cutaneous lupus erythematosus. Both chloroquine and quinacrine (Atabrine) are also effective in this skin disease. Low-dose chloroquine is used for the therapy of porphyria cutanea tarda in patients in whom phlebotomy has failed or is contraindicated. Other skin diseases in which the drugs are useful (after sunscreens and avoidance of sun exposure) include polymorphous light eruption and solar urticaria. [Pg.491]

The principal advantage of MMF over alternative systemic immunosuppressive agents (e.g., methotrexate, cyclosporine) is its relative lack of hepatotoxicity and nephrotoxicity. Adverse effects produced by MMF most commonly include nausea, abdominal cramps, diarrhea, and possibly an increased incidence of viral and bacterial infections. Whether MMF may be associated with an increased long-term risk of lymphoma or other malignancies is controversial however, any such risk is likely to be lower in patients treated for skin disease with MMF monotherapy than in transplant patients treated with combination immunosuppressive therapy. [Pg.493]

Parenteral administration of folic acid is rarely necessary, since oral folic acid is well absorbed even in patients with malabsorption syndromes. A dose of 1 mg folic acid orally daily is sufficient to reverse megaloblastic anemia, restore normal serum folate levels, and replenish body stores of folates in almost all patients. Therapy should be continued until the underlying cause of the deficiency is removed or corrected. Therapy may be required indefinitely for patients with malabsorption or dietary inadequacy. Folic acid supplementation to prevent folic acid deficiency should be considered in high-risk patients, including pregnant women, patients with alcohol dependence, hemolytic anemia, liver disease, or certain skin diseases, and patients on renal dialysis. [Pg.741]

Local therapy, such as topical preparations for skin disease, ophthalmic forms for eye disease, intra-articular injections for joint disease, inhaled steroids for asthma, and hydrocortisone enemas for ulcerative colitis, provides a means of delivering large amounts of steroid to the diseased tissue with reduced systemic effects. [Pg.886]

Osteoporosis induced by chronic glucocorticoid therapy has been reviewed in patients with obstructive lung diseases (195) and patients with skin diseases (196). [Pg.25]

Schopf, E., J.M. Mueller, and T. Ostermann, Value of adjuvant basic therapy in chronic recurrent skin diseases. Neurodermatitis atopica/psoriasis vulgaris. Hautarzt, 1995, 46 451-4. [Pg.141]

Antiseptics and antibiotics are the two hallmarks of antimicrobial therapy. Although there are several reports about local and systemic antimicrobials for therapy of eczematous skin diseases, there is only little data about prevention. [Pg.392]

DNLM 1. Skin Diseases-drug therapy. 2. Emollients—pharmacokinetics. 3. Emollients—therapeutic use. 4. Skin Diseases-physiopathology. WR 650 D798 2005]... [Pg.549]

The answer is yes because there are reported nearly 30,000 diseases or disorders, and only 10,000 of these can be presently treated. This more than justifies the need to develop new drugs. NCEs are required, as drug therapy is unsatisfactory for viral diseases, cancer, and various skin diseases. [Pg.271]

The adrenal cortex synthesizes corticosteroids (glucocorticoids and mineralocor-ticoids), which differ in activities. In humans, cortisol is the main glucocorticoid, and aldosterone is a main mineralocorticoid. Steroid therapy causes severe potential side effects, hence a careful consideration is always exercised before starting therapy. These are used in variety of disorders such as rheumatic disorder, renal disease, allergic manifestation, bronchial asthma, skin diseases, infectious diseases, malignancy, and hepatic diseases. [Pg.286]

Corticosteroids have a range of activity. They have potent antiinflammatory and immunosuppressive activity. Many synthetic drugs are available as corticosteroids. In appropriate doses, these are used as replacement therapy in adrenal insufficiency. The topical application of corticosteroids is safer when compared with systemic use. Corticosteroids should be used in smaller doses for the shortest duration of time. A high dose may be used for life-threatening syndromes or diseases. A tapering pattern of withdrawal should be followed to avoid complications of sudden withdrawal. Systemic therapy is indicated in a variety of conditions. These are administered by intraarticular injections with aseptic conditions for rheumatoid arthritis and osteoarthritis. In skin diseases, such as eczema, contact dermatitis, and psoriasis, corticosteroids are used topically. In some cases, steroids are combined with antimicrobial substances such as neomycin. [Pg.286]

Changes in barrier function due to skin disease generally result either from alteration of the lipid/protein composition of the stratum comeum or from abnormal epidermal differentiation (e.g. in psoriasis). As far as transdermal bioavailability is concerned, however, patches intended for systemic therapy are labelled for application only at normal skin sites, free from dermatologic pathology. [Pg.193]

Topical application (treatment of skin disease). No critical issues here often preferable to systemic therapy... [Pg.11]

Kendall, C. A. and Morton, C. A. (2003). Photodynamic therapy for the treatment of skin disease Technology in Cancer Research Treatment 2 283-288. [Pg.291]

PUVA is used most commonly in the treatment of psoriasis, vitiligo, and cutaneous T-cell lymphoma. However, up to 30 other skin diseases have been reported to be responsive to PUVA therapy. The most common of these include palmarplantar pustulosis, polymorphous light eruption, dishydrotic eczema, atopic dermatitis, allergic contact dermatitis, actinic reticuloid, solar urticaria, pityriasis lichenoides, and graft versus host disease. [Pg.2153]

In many kinds of skin diseases a therapy with UV-light is applied the same lamps are used for cosmetic tanning. Therefore, the different action spectra should be known with high accuracy to avoid unwanted effects. Such action spectra of medical interest are the erythema curve (the action spectrum of sunburn) and action spectra after oral or local administration of photosensitizers. [Pg.46]


See other pages where Skin disease, therapy is mentioned: [Pg.141]    [Pg.299]    [Pg.84]    [Pg.485]    [Pg.159]    [Pg.159]    [Pg.485]    [Pg.141]    [Pg.292]    [Pg.218]    [Pg.391]    [Pg.247]    [Pg.762]    [Pg.42]    [Pg.26]    [Pg.84]    [Pg.3922]    [Pg.86]    [Pg.2153]    [Pg.2154]    [Pg.2155]   
See also in sourсe #XX -- [ Pg.11 ]




SEARCH



Disease therapy

Skin diseases

© 2024 chempedia.info